Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

(marketscreener.com) Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departing March 31 Reprioritization reduces workforce by approximately 20%,...https://www.marketscreener.com/quote/stock/EDITAS-MEDICINE-INC-26123639/news/Editas-Medicine-Announces-Strategic-Updates-and-Portfolio-Reprioritization-42692380/?utm_medium=RSS&utm_content=20230109